Addiction leading to abuse should  be treatable by pharmacological approaches, and programs that identify new drugs to treat methamphetamine abuse address an immediate goal of the National Institute on Drug Abuse (NIDA) that new approaches are needed for treating METH addiction. Currently, small molecule drug-like compounds are not available for treating METH abuse. Neurotensin receptor 1 (NTR1) peptide agonists produce behaviors that are exactly opposite to the psychostimulant effects observed with methamphetamine abuse, such as hyperactivity, neurotoxicity, psychotic episodes, and cognitive deficits, and repeated administrations of NTR1 agonists do not lead to the development of tolerance. These data form the basis of the idea that neurotensin receptors are valid targets for antagonizing drug seeking behaviors and preventing relapses. We propose to identify novel small molecule neurotensin receptor agonists by screening libraries of compounds using a primary assay based upon the ability of a b-arrestin fluorescent reporter to directly recognize the activated state of the NTR1. A. Brief Description of the Assay: This assay is to confirm lead agonists from the primary screening results that activate the neurotensin receptor-1 pathway by detecting of spots of-arrestin-GFP in NTR1-U2OS Osteosarcoma Cells. B. Materials: Description Source Cat NTR1-U2OS osteosarcoma cells Dr. Lawrence Barak, Duke University N/A MEM medium Cellgro/Mediatech 15-010-CM Fetal Bovine Serum Hyclone SH30396.03 Penicillin Streptomycin solution Omega Scientific PS-20 L-Glutamine Mediatech 25-005-CL G418 (100 mg/mL) Invivogen ant-gn-1 Zeocin (100 mg/mL) Invitrogen R250-01 T225 Tissue Culture flasks Corning 431082 DPBS Cellgro 21-031CV Trypsin-EDTA 0.05% Invitrogen 25300 1536 well black clear bottom plate Aurora Biotechnology 29326 NTR1 peptide Sigma N6383 Paraformaldehyde Acros Organics 30528954 Hoechst 33342 (10 mg/mL) Invitrogen H3570 C. Plate Map: Positive (High) control (P) in columns 3 and 4, DMSO and 100 nM NTR1 Negative (Low) control (N) in columns 1 and 2, DMSO but No NTR1 Test compound in columns 5 - 48, Test compound but No NTR1 D. Procedures: Day 1 Step  Description 1 Prepare cell suspension as described in section F. Cell Culture. 2 Set up and prime Combi liquid dispenser 3 Dispense 4 uL/well of cells at 3.5X10;5 cells/mL using Combi into a black 1536 well plate with clear bottom. 4 Spin down plates on Eppendorf centrifuge 5810 at 1000 rpm for 1 minute. 5 Put Kalypsys metal lids on plates, and incubate plates at 37 oC with 5% CO2 overnight. Day 2 Step Description 1 Set up Combi and nL liquid dispensers, Kalypsys plate washer and Opera. 2 Transfer 12.5 nL/well of 10 mM test compounds into assay plates using the Labcyte ECHO 555. The final concentration of compounds is 20 uM with 0.2% DMSO. Compounds are screened in quadruplicates. 3 Add 2 uL/well of 300 nM NTR1 peptide in DPBS to columns 3 and 4 of the assay plates and then add 2 uL/well of DPBS (no peptide) to columns 1, 2, 5-48 using Combi. The final concentration of NTR1 peptide is 100nM. 4 Spin down plates on Eppendorf centrifuge 5810 at 1000 rpm for 1 minute. 5 Incubate plates at 37 oC with 5% CO2 for 1 hour. 6 Fix cells by adding 4 uL/well of 6% Paraformaldehyde into all wells using Combi. The final concentration of Paraformaldehyde is 2.4%. 7 Spin down plates on Eppendorf centrifuge 5810 at 1000 rpm for 1 minute, and Incubate for one hour at room temperature. 8 Wash plates with 1X PBS on the Kalypsys waher by aspirating leaving ~2.5 uL/well and dispensing 11 uL/well DPBS twice, and then aspirating leaving ~2.5 uL/well. 9 Add 5 uL/well of 5 ug/mL Hoechst 33342 diluted in DPBS to assay plates by using Combi nL dispenser. The final concentration of Hoechst 33342 is 3.3 ug/mL. 10 Spin down plates on Eppendorf centrifuge 5810 at 1000 rpm for 1 minute. Then seal plates. 11 Incubate plates for one hour prior to loading to PerkinElmer Opera, or store plates at 4 oC until imaging. E. Recipes: (1) Cell Growth Media and Cell Culture NTR1-U2OS osteosarcoma cells are maintained in MEM growth medium containing 10% Fetal Bovine Serum, 1% Penicillin Streptomycin solution, 1% L-Glutamine with 400 u g/mL G418 and 200ug/mL Zeocin at 37 degrees C with 5% CO2. Discard cells after 20 passages. (2) Assay Media MEM medium containing 2.5 % Fetal Bovine Serum, 1 % Penicillin Streptomycin solution, 1 % L-Glutamine with 400 ug/mL G418 and 200 ug/mL Zeocin. (3) NTR1 peptide solution Step Description 1 Dissolve the powder in 50% Glycerol-H2O at 1 mM. 2 Store it as stock solution at 4 degrees until until just before use. 3 Dilute stock solution (1 mM) to the working conc. of 300 nM in DPBS. *Prepare working solution (300 nM) just before use due to stability issue of the peptide. (4) 6% Paraformaldehyde Solution Step Description 1 Place 2.4 L of MilliQ H2O on a container and pH to 11 using NaOH while stirring. 2 Add 180 g of Paraformaldehyde powder gently into solution. 3 Keep stirring at room temp until it is completely dissolved (this can take several hours). 4 Adjust pH to 7.4 using H2SO4 (not HCL). 5 Add MilliQ H2O to have the solution final volume 3L. 6 Store the solution at 4 degrees. Protect from light. It can be stored up to a week. (5) Hoechst solution Step Description 1 Dilute stock solution (10 mg/mL) to the working conc. of 5 ug/mL in DPBS. J. Image Acquisition and Analysis: 1) Image acquisition was performed on an Opera QEHS (Perkin Elmer) with 45 plate capacity loader/stacker and the following settings: - 40x 0.6 NA air objective - Acquisition camera set to 2-by-2 binning for an image size of 688 by 512 pixels - 2 channels acquired sequentially: 1) Beta-arrestin-GFP using 488 nm laser excitation and 540/75 nm emisssion filters, 2) DAPI (nuclei) using 365 nm Xenon lamp excitation and 450/50 nm emission filters - 3 fields per well for Primary screen 2) Image analysis was performed using the Acapella Spot Detection Algorithm with the following analysis settings: NUCLEI DETECTION - Threshold Adjustment: 1.5 - Minimum Nuclei distance: 7 - Nuclear Splitting Adjustment: 7 -Individual Threshold Adjustment: 0.4 - Minimum Nuclear Area: 70 - Minimum Nuclear Contrast: 0.1 CYTOPLASM DETECTION - Cytoplasm Individual Threshold Adjustment: 0.1 SPOT DETECTION - Spot Minimum Distance: 3 - Spot Peak Radius: 0 - Spot Reference Radius: 3 - Spot Minimum Contrast: 0.4 - Spot Minimum to Cell Intensity: 1 3) Metrics calculated from... NUCLEI IMAGES: Cell Count ("CellCount"), Nuclei Area ("NuclearArea"), Integrated Intensity of the Nuclei ("TotNucIntensity"), Average Intensity of the Nuclei ("AvgNucIntensity"); GFP IMAGES: Average Intensity of the Cytoplasm ("AvgCytoIntensity"), Average Intensity of the Cell ("AvgCellIntensity"), Integrated Intensity of the Cell ("TotCellIntensity"), Integrated Intensity of the Cytoplasm ("TotCytoIntensity"), Integrated Intensity of the Detected Spots ("TotSpotIntensity"), Ratio of the Integrated Spot to Integrated Cytoplasm Intensities ("RatioTotSpotIntensity2CellIntensity"), Number of Spots per Cell ("AvgSpotPerCell"), Average Area of Spots ("AvgSpotAreaPerCell").
bao:BAO_0000540 "493036" ; # "is confirmatory assay of" -> "493036"
bao:BAO_0000812 "493055" ; # "has summary assay" -> "493055"
bao:BAO_0000809 bao:BAO_0000030 ; # "has confirmatory assay" -> "confirmatory assay"
bao:BAO_0000205 bao:BAO_0000219 ; # "has assay format" -> "cell-based format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000284 ; # "has participant" -> "G protein coupled receptor" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0000378 ; # "is bioassay type of" -> "protein redistribution assay"
bao:BAO_0000212 bao:BAO_0000126 ; # "has assay method" -> "molecular redistribution determination method"
bao:BAO_0000207 bao:BAO_0000363 ; # "has detection method" -> "fluorescence intensity"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Agonists of Neurotensin Receptor type 1 (NTR1)" ; # "screening campaign name" -> "Agonists of Neurotensin Receptor type 1 (NTR1)"
bao:BAO_0002853 "Single concentration confirmation of Image-Based HTS for Selective Agonists for NTR1" ; # "has assay title" -> "Single concentration confirmation of Image-Based HTS for Selective Agonists for NTR1"
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000536 ; # "has concentration throughput" -> "single concentration"
bao:BAO_0000109 "37 degree celsius" ; # "has temperature value" -> "37 degree celsius"
bao:BAO_0002833 "1 hour" ; # "has incubation time value" -> "1 hour"
bao:BA0_0090012 "\"NTR1 peptide 100 nM, Sigma N6383, dmso\"" ; # "has participant" -> ""NTR1 peptide 100 nM, Sigma N6383, dmso""
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Lawrence Barak" ; # "material entity assay provider" -> "Lawrence Barak" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000373 ; # "has assay phase characteristic" -> "heterogeneous phase"
bao:BA0_0090012 "Neurotensin receptor type 1" ; # "has participant" -> "Neurotensin receptor type 1"
bao:BAO_0002004 <http://purl.obolibrary.org/obo/CLO_0009454> ; # "has cell line" -> "U-2 OS cell"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "4923" ; # "gene ID" -> "4923"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P30989" ; # "uniprot ID" -> "P30989"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10% fetal bovine serum" ; # "material entity culture serum" -> "10% fetal bovine serum" || bao:BAO_0003102 bao:BAO_0002596 ; # "has role" -> "culture serum"
bao:BAO_0002922 "\"MEM with 2.5% FBS, 1% Penicillin Streptomycin solution, 1% L-Glutamine, 400 microg/mL G418 and 200 microg/mL Zeocin\"" ; # "has assay medium" -> ""MEM with 2.5% FBS, 1% Penicillin Streptomycin solution, 1% L-Glutamine, 400 microg/mL G418 and 200 microg/mL Zeocin""
bao:BAO_0002922 bao:BAO_0000596 ; # "has assay medium" -> "assay medium"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2.5% fetal bovine serum" ; # "material entity assay serum" -> "2.5% fetal bovine serum"
bao:BAO_0002923 bao:BAO_0002597 ; # "has assay serum" -> "assay serum"
bao:BAO_0000212 bao:BAO_0000246 ; # "has assay method" -> "stable transfection"
bao:BAO_0000550 "Expressing a beta-arrestin GFP biosensor and neurotensin receptor type 1" ; # "DNA construct" -> "Expressing a beta-arrestin GFP biosensor and neurotensin receptor type 1"
bao:BAO_0003105 "neurotensin receptor 1 (high affinity)" ; # "has function" -> "neurotensin receptor 1 (high affinity)"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "4923" ; # "construct gene ID" -> "4923"
bao:BAO_0003105 "beta-arrestin GFP" ; # "has function" -> "beta-arrestin GFP" || bao:BAO_0003102 bao:BAO_0002656 ; # "has role" -> "reporter gene"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0000854 ; # "has participant" -> "Arrestin-GFP"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0002153 ; # "has signal direction" -> "signal increase corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000982 ; # "uses detection instrument" -> "Opera QEHS"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "488 nanometer" ; # "has excitation wavelength value" -> "488 nanometer"
bao:BAO_0002917 "365 nanometer" ; # "has excitation wavelength value" -> "365 nanometer"
bao:BAO_0002918 "540 nanometer" ; # "has emission wavelength value" -> "540 nanometer"
bao:BAO_0002918 "450 nanometer" ; # "has emission wavelength value" -> "450 nanometer"
bao:BAO_0000337 bao:BAO_0000200 ; # "has percent response" -> "percent activation"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has concentration unit" -> "percent"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1" ; # "PubChem TID" -> "1"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002666 "20" ; # "has concentration value" -> "20"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0002845 "4" ; # "has repetition point-number" -> "4"
bao:BAO_0000196 bao:BAO_0000087 ; # "has mode of action" -> "activation"
bao:BAO_0002864 bao:BAO_0000533 ; # "has repetition throughput" -> "multiple repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "mp" ; # "Annotated by" -> "mp"
